Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)
- To quantify HIV-1 persistence in prospectively collected samples from patients on
suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma.
OUTLINE: This is a multicenter study.
Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA
levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood
After completion of treatment, patients are followed up periodically for up to 2 years.
Observational Model: Cohort, Time Perspective: Prospective
Change in viral load from baseline to each subsequent time point
Time frame for outcome measures dependent on study calendar for parent protocol, S0816, which varies by subject's PET scan status.
Baseline, after each cycle of treatment, restaging, treatment completion, year 1, year 2, study discontinuation
John W. Mellors, MD
University of Pittsburgh
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|